Abstract
Background: Accumulating evidence suggests serum levels of microRNA (miR)-371a-3p to be a novel tumour marker of testicular germ cell tumours (GCTs). Presently, there is only limited information regarding the velocity of decline of serum levels in response to treatment. Patients and Methods: Twenty-four patients with testicular GCT (20 seminoma, 4 nonseminoma, median age 40 years) with clinical stage 1 had measurements of serum levels of miR-371a-3p preoperatively and repeatedly on the following 3 days. Three had additional tests done within 24 h after surgery. Measurement results were analysed using descriptive statistical methods. Results: Serum levels dropped to 2.62, 1.27, and 0.47% of the preoperative level within 1, 2, and 3 days, respectively. The computed half-life amounts to 3.7-7 h. The velocity of decay is significantly associated with tumour size. Conclusions: Serum-levels of miR-371a-3p have a short half-life of less than 12 h. The rapid decay after treatment represents a valuable feature confirming the usefulness of miR-371a-3p as a valuable serum biomarker of GCT.
Author supplied keywords
Cite
CITATION STYLE
Radtke, A., Hennig, F., Ikogho, R., Hammel, J., Anheuser, P., Wülfing, C., … Dieckmann, K. P. (2018). The novel biomarker of germ cell tumours, Micro-RNA-371a-3p, Has a very rapid decay in patients with clinical stage 1. Urologia Internationalis, 100(4), 470–475. https://doi.org/10.1159/000488771
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.